Analyzing the Potential of AAV2-GDNF Gene Thera...

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson’s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression. Risvo...

Ocrelizumab proves superior to first-line therapies in early RRMS, promoting better outcomes. Long-term data spanning a decade validate Ocrelizumab’s sustained efficacy and safety across MS stages, enhancing patient management. At the 2024 American Academy of Neurology conference, significant findings were ...

DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who experience challenges with sleep onset and/or maintenance. It has received approval for insomnia treatment in over 15 countries, such as Japan, the United States, Canada, Australia, and various Asian nati...

Biohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by providing innovative therapeutic choices with improved tolerability for epilepsy patients.  BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, presents a promising avenue, navigatin...

Fenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to treat relapsing and primary progressive MS.  Fenebrutinib treatment resulted in decreased new lesion activity and enhanced penetration into the cerebrospinal fluid (CSF) in multiple sclerosis (MS...

iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. i...